Thanks @JabraD.
Thesis hasn't changed. Two years on, we've proven that GLP-1 agonists reduce intracranial pressure in a Phase 2 and we have our manufacturing and tox sorted. COVID slowed the reformulation efforts but Peptron's PT302 was a neat sidestep that sped things up again.
The direction has changed. We're not going for every raised intracranial pressure indication, just IIH and a proof of study in another indication e.g. TBI.
The timeline has also changed. We're looking at a buyout mid 2024 post Phase 3 results. Whether they will surprise us with a FDA NDA on the strength of the EVOLVE study prior to selling the company remains to be seen.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
9.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.763M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 41290 | 8.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.9¢ | 59180 | 2 |
View Market Depth
| Last trade - 16.21pm 11/07/2025 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable